@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2/3 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
✅3 agents (pembro, atezo, cempilimab) 👍🏽PD-L1 TPS >50% in 1L
– No head to head ICI comparisons
✅OS BETTER w IO alone vs chemo
✅💰tox huge problem!
📚We captured the convo in this moment:
twitter.com/i/events/15675…
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2.5/3 #TumorBoardTuesday
Thurs Case🎀
Key factors to choose ICI (in absence of head to head trials):
- Pt experiences/preferences
- Dosing schedule
- $$$ toxicity
The good news: across 3 separate agents (pembrolizumab, atezolizumab, cemiplimab) OS is BETTER w IO alone vs chemo
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers 3/3
Thurs Case🎀
Thanks for joining us for #TumorBoardTuesday!
Some scheduling notes:
@jane_meisel’s #BRCA case is rescheduled for 12.20.22
➡️Please be sure to join us on 09/20/22 when @maryam_lustberg @JasmineSukumar present a case focused on PIK3CA inhibition in #mBC 😀
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers @jane_meisel @maryam_lustberg @JasmineSukumar ...and before we close out this #TumorBoardTuesday case wrap up, we have to acknowledge @ShrutiPatelMD's meme game:
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers @jane_meisel @maryam_lustberg @JasmineSukumar Remember #TumorBoardTuesday continues to offer AMA & MOC credit for FREE!
Don’t forget to answer the polls👇🏽
Click this link to quickly request your credit!
CME eval🔗: integrityce.com/tbteval
ALL CME 🔗: integrityce.com/tbt
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers @jane_meisel @maryam_lustberg @JasmineSukumar @dawood_findakly @ALKpositiveINT @HannahAlison20 @JineshGheeya @LatinasInMed @FawziAbuRous @LatinxOncology @FernandoDiazMD1 @KellyMezaMD @MomaVelez11 @SarahGhosh20 @MNagasaka @KanKParmar @CaThompsonMD @s_brond @GallodeMoraesMD @esinghimd @OMETinyHeartsMD @KinhHoangMD @AnaVManana
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers @jane_meisel @maryam_lustberg @JasmineSukumar @ALKpositiveINT @HannahAlison20 @JineshGheeya @LatinasInMed @FawziAbuRous @FernandoDiazMD1 @KellyMezaMD @MomaVelez11 @SarahGhosh20 @MNagasaka @KanKParmar @CaThompsonMD @s_brond @GallodeMoraesMD @OMETinyHeartsMD @AnaVManana @anguspratt @OPENoncology @jennifermarksmd @drkevinknopf @drpushkal1 @GiulyPalumbo @Harshadod @ADesaiMD @OncBrothers @Angela_Ai_ @JFreemanDaily @paulalv @acmoorephd @jillfeldman4 @tanyawildes @Gr8Engineering @RenoHemonc @ChrisJ_Shepherd
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers @jane_meisel @maryam_lustberg @JasmineSukumar @ALKpositiveINT @HannahAlison20 @JineshGheeya @LatinasInMed @FawziAbuRous @FernandoDiazMD1 @KellyMezaMD @MomaVelez11 @SarahGhosh20 @MNagasaka @KanKParmar @CaThompsonMD @s_brond @GallodeMoraesMD @OMETinyHeartsMD @AnaVManana @anguspratt @OPENoncology @jennifermarksmd @drkevinknopf @n8pennell @drRTee @CharuAggarwalMD @CatherineShuMD @VivekSubbiah @DevikaDasMD
@letswinpc @GlopesMd @Latinamd @DrSteveMartin @manalipatelmd @FredrikThege @Aiims1742 @jacobadashek
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.
